EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access

Pharmacokinetics and Bioavailability of a Novel Rivastigmine Nasal Spray Compared to Rivastigmine Oral Capsule in Healthy Men

Timothy M Morgan iD, Benjamin Snyder

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70086 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Timothy M Morgan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lachesis Biosciences Ltd., Breakwater, Victoria, Australia. Hauptthemen laut MEDLINE: Phenylcarbamates, Cholinesterase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Lachesis Biosciences and AusIndustry, Australian New Zealand Clinical Trials Registry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To compare the pharmacokinetics, bioavailability, tolerability, and safety of a novel 4 mg rivastigmine nasal spray to 3 mg rivastigmine oral capsule, a single‐dose, open‐label, randomized, crossover study was conducted in 16 fasted healthy young men (18 to 55 years). Mean (SD) rivastigmine C max was 8.39 (6.8) and 13.77 (10.7) ng/mL for oral and nasal, respectively. Rivastigmine AUC 0‐inf was 19.6 (14.9) and 40.6 (24.4) ng h/mL for oral and nasal, respectively. The ratio of LS means (nasal test / oral reference; 90% C.I.) for rivastigmine C max was 185.83% (134.22, 257.28) and for rivastigmine AUC 0‐inf was 257.35% (197.26, 335.73). Rivastigmine t max for nasal (0.7 h) was significantly lower than oral (1.2 h, P < .05), however, NAP226‐90 t max for nasal (1.9 h) and oral (1.8 h) were similar. NAP226‐90 C max was 3.93 (1.1) and 3.01 (0.8) ng/mL for oral and nasal, respectively. NAP226‐90 AUC 0‐inf was 22.9 (5.3) and 23.2 (5.1) ng h/mL for oral and nasal, respectively. Median NAP226‐90 to rivastigmine AUC 0‐inf ratio for nasal (0.55) was significantly lower than oral (1.38, P < .05) because nasal bypassed first‐pass metabolism. Both single‐dose treatments were safe and well tolerated. Nasal and throat irritation were mostly perceived as mild and transient following nasal administration. The 4 mg rivastigmine nasal spray had 1.5‐ and 2.0‐fold higher dose normalized rivastigmine C max and AUC 0‐inf , respectively, and 2.5‐fold lower NAP226‐90 to rivastigmine AUC 0‐inf ratio compared to 3 mg oral capsule. This nasal spray has good potential to improve the local and gastrointestinal tolerability of rivastigmine treatment in Alzheimer's and Parkinson's disease dementia patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylcarbamatesCholinesterase InhibitorsHumansMaleRivastigmineAdultCross-Over StudiesBiological AvailabilityAdministration, OralYoung AdultMiddle AgedNasal SpraysAdolescentCapsulesAdministration, IntranasalArea Under Curve

Stichwörter der Autor:innen

bioavailabilitydementiahumannasaloralrivastigmine

Substanzen

RivastigmineNasal SpraysPhenylcarbamatesCapsulesCholinesterase Inhibitors

Autor:innen und Institutionen

  • Lachesis Biosciences Ltd., Breakwater, Victoria, Australia.
  • Nucleus Network, Department of General Medicine, Alfred Health, Melbourne, Victoria, Australia.

ORCID-Profile: Timothy M Morgan

Förderung

  • Lachesis Biosciences and AusIndustry
  • Australian New Zealand Clinical Trials Registry

Zitieren

APA

Morgan, T. M., & Snyder, B. (2026). Pharmacokinetics and Bioavailability of a Novel Rivastigmine Nasal Spray Compared to Rivastigmine Oral Capsule in Healthy Men. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70086

Vancouver

Morgan TM, Snyder B. Pharmacokinetics and Bioavailability of a Novel Rivastigmine Nasal Spray Compared to Rivastigmine Oral Capsule in Healthy Men. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70086

BibTeX
@article{Morgan2026,
  author = {Morgan, Timothy M and Snyder, Benjamin},
  title = {Pharmacokinetics and Bioavailability of a Novel Rivastigmine Nasal Spray Compared to Rivastigmine Oral Capsule in Healthy Men},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70086}
}
Kostenlos starten →